Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1Genitourinary 1

Conditions

Urologic Diseases 1Nephritis 1Kidney Diseases 1Immune System Diseases 1Glomerulonephritis, IGA 1Glomerulonephritis 1Autoimmune Diseases 1

Interventions

Docetaxel 390pembrolizumab 325Prednisone 284Gemcitabine 273enzalutamide 254Radiotherapy 251Nivolumab 247Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 197Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 98cabozantinib 97abiraterone 97Sorafenib 97atezolizumab 96Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Valsartan × Genitourinary × Clear all
NCT02765594 2017-09-20

HCQIgAN

Peking Union Medical College Hospital

Phase 4 Unknown
98 enrolled
Genitourinary

Autoimmune Diseases, Glomerulonephritis, Glomerulonephritis, IGA, Immune System Diseases, Kidney Diseases, Nephritis, Urologic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡